EarningsQ2 2026 Earnings Report
DE:OM2 Q2 2026 EPS Results
Actual EPS-€0.35
Consensus EPS-€0.37
Beat/MissBeat by +€0.02
One Year Ago EPS-€0.32
DE:OM2 Q2 2026 Revenue Results
Actual Revenue€188.00M
Expected Revenue€186.53M
Beat/MissBeat by +€1.48M
YoY Revenue Growth+3.85%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
DE:OM2 Upcoming Earnings
Orthofix Medical's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:OM2 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: multiple business segments showed tangible improvement (5% consolidated pro forma growth, strong Spine Fixation and Limb Reconstruction results, stabilization in Biologics, and restored Medicare reimbursement), management raised full-year sales and EBITDA guidance, and product launches/clinical investments provide future upside. Offsetting these positives are persistent execution risks—notably underperformance among smaller U.S. spine distributors, geographic mix and credit-loss impacts on margins, and a temporary, timing-driven European MDR-related revenue boost that will reverse in 2027 and create cash timing pressure. The company appears to be in a transition toward higher-quality, more profitable growth but remains exposed to near-term execution and timing risks.Company Guidance
Company-wide Net Sales Growth and Raised Guidance
Orthofix reported 5% pro forma constant currency net sales growth in Q2 2026 versus prior year and raised full-year 2026 net sales guidance to $845M–$855M (approximately 5% growth at the midpoint), a $7M increase from May guidance.
Segment Outperformance — Spine Fixation
Global Spine Fixation net sales grew 10% on a constant currency basis (U.S. Spine Fixation up 3% in the quarter). Initial clinical cases were completed for the VIRATA minimally invasive system with a planned full market launch of the VIRATA Spinal Implant System in Q4; early surgeon feedback was encouraging.
Therapeutic Solutions Resilience and Reimbursement Restoration
Therapeutic Solutions (formerly Bone Growth Therapies) delivered 3% year-over-year net sales growth to $64.2M despite temporary Medicare reimbursement pressure. CMS restored Medicare reimbursement retroactive to May 18, 2026 (stated ~ $12M benefit), removing a meaningful headwind for H2 2026 and improving visibility.
Global Limb Reconstruction Strength
Global Limb Reconstruction net sales increased 11% on a constant currency basis to $37.7M, driven by international momentum and adoption of TrueLok Elevate and FITBONE; U.S. growth remains more modest while commercial infrastructure is built.
Biologics Stabilization and Targeted Clinical Investment
Biologics moved from double-digit declines in 2025 to approximately flat year-over-year in Q2 (second consecutive quarter of improvement). Management is investing in clinical evidence for OsteoCove and Virtuos and launching a product registry for Strand Plus to support durable recovery and growth.
Profitability and Liquidity Position
Non-GAAP adjusted gross margin was 71.7% and adjusted EBITDA was $20.1M for Q2. Company ended the quarter with $104.4M in total cash. Full-year adjusted EBITDA guidance was increased to $95M–$98M, reflecting restored reimbursement, cost actions, and operational progress.
DE:OM2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed